Regenexx

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Regenexx sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 2 currently recruiting 5 completed early-phase tilt top decile by trial count

Regenexx: 13 sponsored US clinical trials, 2 recruiting.

Regenexx sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Knee Osteoarthritis, with 2 trials.

Top-decile sponsor footprint

Regenexx ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

5 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (45.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING NA

Trial for Treating Painful Degenerative Disc Disease

NCT05287867
RECRUITING NA

Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries

NCT03517761
TERMINATED NA

Platelet Lysate vs Saline for Lumbosacral Radiculopathy

NCT06924853
COMPLETED NA

Randomized Trial of Regenexx Stem Cell Support Formula

NCT04661267
TERMINATED NA

Nebulized PL for Post-COVID-19 Syndrome

NCT04487691
TERMINATED NA

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
TERMINATED NA

Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study

NCT03898388
COMPLETED Phase 1

Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage

NCT03120988
TERMINATED

A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

NCT02370823
COMPLETED NA

Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA

NCT02034032
COMPLETED NA

Regenexx™ SD Versus Exercise Therapy for ACL Tears

NCT01850758
TERMINATED NA

Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy

NCT01850771
COMPLETED NA

Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears

NCT01788683

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Knee Osteoarthritis 2
Anterior Cruciate Ligament Tear 1
Craniocervical Injuries 1
Rotator Cuff Tear 1
Degenerative Disc Disease 1

What is open in the Regenexx pipeline

2 recruiting of 13 indexed (15% open); 5 completed (38%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Knee Osteoarthritis (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Regenexx: open-pipeline peers nationwide

Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Regenexx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%5%10%15%20% Total trials Recruiting share RegenexxAdaptimmuneAgennixAkili Interactive LabsAlumisArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
Regenexx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Regenexx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Regenexx page

13 registered trials is a research-attention snapshot, not an endorsement of Regenexx or any single study.

  • 2 of Regenexx's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Knee Osteoarthritis is the condition Regenexx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Knee Osteoarthritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Regenexx pipeline card: 13 registered trials from official public datasets.Report a data error.